The DETOUR® System Resources

Evidence, education and tools for the DETOUR® System.

Endologix LLC is the legal manufacturer of the company's devices.

PTAB with the DETOUR System Launch Video

MM2663-US Rev 02

DETOUR System Procedural Animation

MM2589-US Rev 03

Podcast – Treating Complex PAD via Percutaneous Transmural Arterial Bypass

MM2727-US Rev 01

Webinar – Discussion with the Authors of Published Article about PTAB

MM2733-US Rev 01

Revascularizing Complex SFA Lesions and CTOs: Is it PTAB with the DETOUR System Time?

MM2716-US Rev 01

PTAB With the DETOUR® System for the Management of Long SFA Disease

MM2825-US Rev 01

DETOUR System Brochure

MM2655-US Rev 03

DETOUR System Clinical Data Summary

MM2752-US Rev 02

DETOUR System Patient Brochure

MM2658-US Rev 02

DETOUR System Patient Brochure (Spanish Translation)

MM2658-US-ES-XL Rev 01

DETOUR System Coding Guide

MM2710-US Rev 04

Reimbursement Frequently Asked Questions

MM2709-US Rev 04

New Technology Add-on Payment Overview

MM2734-US Rev 02

DETOUR System TPT Overview

MM2754-US Rev 02

Percutaneous Transmural Arterial Bypass (PTAB): A Novel Addition to the Treatment Options for Symptomatic PAD

MM2835-US Rev 01

EVT Tech Article Supplement

MM2852-US Rev 01

HMP CME Program: A New Option for Those With No Option

Rhevera Medical Holdings is the parent company of Endologix LLC. Endologix LLC is the legal manufacturer of the company's devices.

Legal Information:

INDICATIONS FOR USE:
The DETOUR® System is indicated for use for percutaneous revascularization in patients with symptomatic femoropopliteal lesions from 200mm to 460mm in length with chronic total occlusions (100mm to 425mm) or diffuse stenosis >70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments. The DETOUR® System, or any of its components, is not for use in the coronary and cerebral vasculature.

CONTRAINDICATIONS:
The DETOUR® System is contraindicated in patients with:

A distal common femoral artery (CFA) <7 mm in diameter.
Increased risk of deep vein thrombosis (DVT), such as patients with a recent history of DVT, thrombophilia, and disseminated malignancy.
Untreated flow-limiting aortoiliac occlusive disease.
Lack of patent single vessel tibial runoff to ankle.
Known coagulopathy, bleeding diathesis, or thrombocytopenia that cannot be medically managed.
Known hypersensitivities, allergies or contraindications to: Nitinol; PTFE; aspirin; heparin; antiplatelet; anticoagulant or thrombolytic therapy; or contrast media that cannot otherwise be medically managed.

Refer to Instructions for Use for more information concerning Indications, Contraindications, Specific Anatomic Considerations, Warnings, Precautions, and Adverse Events.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.

NOTE: Not all product components are available in every country.

Endologix is a registered trademark of Endologix LLC in the United States, Europe and Japan, and Rhevera, Rhevera Medical, the Rhevera logo, ALTO, AFX, Detour and Pounce are trademarks of Endologix LLC and its subsidiaries. All other trademarks are the property of their respective owners.